Mangoceuticals (NASDAQ:MGRX – Get Free Report) announced its quarterly earnings data on Friday. The company reported ($0.69) earnings per share (EPS) for the quarter, Zacks reports. The business had revenue of $0.08 million for the quarter. Mangoceuticals had a negative net margin of 2,757.86% and a negative return on equity of 85.01%.
Mangoceuticals Stock Performance
Shares of MGRX stock opened at $1.48 on Friday. The firm has a market cap of $15.60 million, a P/E ratio of -0.42 and a beta of 2.39. The firm’s 50 day moving average price is $2.19 and its 200-day moving average price is $1.93. Mangoceuticals has a one year low of $0.98 and a one year high of $6.15.
Wall Street Analyst Weigh In
A number of brokerages recently commented on MGRX. Weiss Ratings reiterated a “sell (e+)” rating on shares of Mangoceuticals in a research report on Tuesday. Wall Street Zen upgraded Mangoceuticals from a “sell” rating to a “hold” rating in a report on Saturday, August 16th. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company presently has a consensus rating of “Sell”.
Institutional Investors Weigh In On Mangoceuticals
A hedge fund recently raised its stake in Mangoceuticals stock. Geode Capital Management LLC raised its position in Mangoceuticals, Inc. (NASDAQ:MGRX – Free Report) by 35.4% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 26,498 shares of the company’s stock after purchasing an additional 6,928 shares during the period. Geode Capital Management LLC owned 0.51% of Mangoceuticals worth $40,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 56.72% of the company’s stock.
Mangoceuticals Company Profile
Mangoceuticals, Inc develops, markets, and sells various men's wellness products and services through a telemedicine platform in the United States. It offers erectile dysfunction (ED) products under the Mango brand and hair loss products under the Grow brand name. The company markets and sells these branded ED and hair loss products online through its website at MangoRx.com.
Read More
- Five stocks we like better than Mangoceuticals
- NYSE Stocks Give Investors a Variety of Quality Options
- Disney Stock Drops—Will Earnings Pave Way for a YouTube TV Truce?
- How to invest in marijuana stocks in 7 steps
- Meta’s Pain May Be Your Gain: Is This a Rare Buying Window?
- The Most Important Warren Buffett Stock for Investors: His Own
- 3 Under-the-Radar AI Stocks to Buy on the Dip
Receive News & Ratings for Mangoceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mangoceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
